JP2025509564A - 抗trop2抗体-薬物コンジュゲート治療のためのスコアリング方法 - Google Patents

抗trop2抗体-薬物コンジュゲート治療のためのスコアリング方法 Download PDF

Info

Publication number
JP2025509564A
JP2025509564A JP2024554777A JP2024554777A JP2025509564A JP 2025509564 A JP2025509564 A JP 2025509564A JP 2024554777 A JP2024554777 A JP 2024554777A JP 2024554777 A JP2024554777 A JP 2024554777A JP 2025509564 A JP2025509564 A JP 2025509564A
Authority
JP
Japan
Prior art keywords
cancer
adc
optical density
antibody
positive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024554777A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509564A5 (cg-RX-API-DMAC7.html
Inventor
スピッツミューラー,アンドレア
シュミット,ギュンター
トリルシュ,ニコラス
カピル,アンシュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of JP2025509564A publication Critical patent/JP2025509564A/ja
Publication of JP2025509564A5 publication Critical patent/JP2025509564A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oncology (AREA)
JP2024554777A 2022-03-16 2023-03-14 抗trop2抗体-薬物コンジュゲート治療のためのスコアリング方法 Pending JP2025509564A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263320629P 2022-03-16 2022-03-16
US63/320,629 2022-03-16
PCT/IB2023/052428 WO2023175483A1 (en) 2022-03-16 2023-03-14 A scoring method for an anti-trop2 antibody‑drug conjugate therapy

Publications (2)

Publication Number Publication Date
JP2025509564A true JP2025509564A (ja) 2025-04-11
JP2025509564A5 JP2025509564A5 (cg-RX-API-DMAC7.html) 2026-03-19

Family

ID=85776040

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024554777A Pending JP2025509564A (ja) 2022-03-16 2023-03-14 抗trop2抗体-薬物コンジュゲート治療のためのスコアリング方法

Country Status (8)

Country Link
EP (1) EP4493933A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025509564A (cg-RX-API-DMAC7.html)
KR (1) KR20240165390A (cg-RX-API-DMAC7.html)
CN (1) CN118891525A (cg-RX-API-DMAC7.html)
AU (1) AU2023235490A1 (cg-RX-API-DMAC7.html)
CA (1) CA3255700A1 (cg-RX-API-DMAC7.html)
IL (1) IL315662A (cg-RX-API-DMAC7.html)
WO (1) WO2023175483A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202619750A (zh) 2024-09-06 2026-05-16 英商阿斯特捷利康英國股份有限公司 抗trop2抗體-藥物結合物療法之評分方法
CN119986001B (zh) * 2025-01-23 2026-04-07 中山大学孙逸仙纪念医院 试剂盒及其在预测trop2-adc疗效中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
DE69521002T3 (de) 1994-08-12 2010-02-25 The University Of Utah Research Foundation, Salt Lake City Mutationen des mit 17q verbundenen Ovarial- und Brustkrebs Empfindlichkeitsgens
EP0699754B2 (en) 1994-08-12 2009-08-12 The University of Utah Research Foundation Method for diagnosing a predisposition for breast and ovarian cancer
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
US7420040B2 (en) * 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
CA2647632C (en) 2006-03-27 2017-06-27 University Of Maryland Biotechnology Institute Glycoprotein synthesis and remodeling by enzymatic transglycosylation
JP6282232B2 (ja) 2012-02-10 2018-02-21 ユニバーシティー オブ メリーランド,ボルティモア 抗体及びそのFcフラグメントの酵素化学的糖鎖改変
ITCH20120008A1 (it) * 2012-05-16 2013-11-17 Saverio Alberti Uso di trop-2 come marcatore predittivo di risposta a terapia anti-tumorale basata su inibitori di cd9, akt e vie di segnale collegate
US10195288B2 (en) 2012-10-11 2019-02-05 Daiichi Sankyo Company, Limited Antibody-drug conjugate
US10241115B2 (en) * 2013-12-10 2019-03-26 Merck Sharp & Dohme Corp. Immunohistochemical proximity assay for PD-1 positive cells and PD-ligand positive cells in tumor tissue
SG10201902571VA (en) 2013-12-25 2019-04-29 Daiichi Sankyo Co Ltd Anti-trop2 antibody-drug conjugate
SG11201603960XA (en) 2014-01-31 2016-07-28 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugate
TWI871999B (zh) 2014-04-10 2025-02-01 日商第一三共股份有限公司 抗her3抗體-藥物結合物
PT3313443T (pt) * 2015-06-25 2023-08-30 Immunomedics Inc Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
CA2990572C (en) 2015-06-29 2022-07-26 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
CN108601841A (zh) * 2016-02-10 2018-09-28 免疫医疗公司 Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性
ES2885178T3 (es) * 2017-02-06 2021-12-13 Novartis Ag Método para la predicción de respuesta a la inmunoterapia
EP3677589B1 (en) 2017-08-31 2025-11-26 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate

Also Published As

Publication number Publication date
WO2023175483A1 (en) 2023-09-21
AU2023235490A1 (en) 2024-09-26
CN118891525A (zh) 2024-11-01
IL315662A (en) 2024-11-01
CA3255700A1 (en) 2023-09-21
EP4493933A1 (en) 2025-01-22
KR20240165390A (ko) 2024-11-22

Similar Documents

Publication Publication Date Title
KR101982317B1 (ko) Folr1 암 치료의 효능을 증가시키기 위한 방법
CN103154741B (zh) 含有抗体作为成分的医药品的有效性的判定方法
WO2021260583A1 (en) Combination of antibody-drug conjugate and dna-pk inhibitor
AU2021340002B2 (en) A scoring method for an anti-her2 antibody-drug conjugate therapy
TWI822822B (zh) 抗體-藥物結合物之用途
WO2022102695A1 (ja) 抗b7-h3抗体-薬物コンジュゲート投与による中皮腫の治療
WO2011162904A2 (en) Multidomain biotags for cancer detection, diagnosis and therapy and methods of their use priority statement
CN106456748A (zh) 小细胞肺癌的靶向疗法
KR20240165390A (ko) 항-trop2 항체-약물 접합체 요법에 대한 점수산정 방법
EP4676541A1 (en) Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-vegfr-2 antibodies and anti-pd1/pd-l1 antibodies
EP4211663B1 (en) A scoring method for an anti-b7h4 antibody-drug conjugate therapy
US20150293105A1 (en) Methods for classifying tumors and uses therefor
WO2026052764A1 (en) A scoring method for an anti-trop2 antibody drug conjugate therapy
CN115884794A (zh) 抗her2抗体药物缀合物与her二聚化抑制剂的组合
TW202535479A (zh) 抗體藥物結合物與血腦屏障穿透性parp1選擇性抑制劑之組合
WO2020219854A1 (en) Netrin g1 and netrin g1 ligand peptides and antibodies and uses thereof
EA053283B1 (ru) Лечение метастатической опухоли головного мозга путем введения конъюгата антитело-лекарственное средство

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260311